FDA Grants Breakthrough Therapy Designation for Debiopharm’s Novel Chemo-Radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer

LAUSANNE, Switzerland, Feb. 27, 2020 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced that the American Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for Debio 1143, the most clinically advanced IAP antagonist, for the treatment of patients with confirmed diagnosis of previously untreated, unresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in combination with current standard of care, cisplatin-based concomitant standard fractionation chemoradiation therapy (CRT). Ongoing clinical investigations have been developed to evaluate the benefit of increasing tumor cell sensitivity to CRT, making the addition of Debio 1143 a highly promising strategy for radio-oncologists to improve treatment outcomes for high-risk LA-SCCHN.

This Breakthrough Therapy Designation is based on the clinically compelling phase II study results (NCT02022098) presented at the ESMO Congress 2019 in Barcelona, Spain. They revealed a very significant improvement of the primary endpoint locoregional control rate at 18 months after CRT (21% improvement vs. control arm) and a marked Progression-Free Survival (PFS) benefit vs. the CRT+placebo arm after a 2-year follow-up period (HR=0.37, p=0.007). In addition, the compound showed a predictable and manageable safety profile, that did not compromise the full delivery of standard CRT.  

"Despite today's current standard of care, high-risk locally-advanced head and neck cancer remains an area of unmet medical need.  This Breakthrough Therapy Designation will allow us to maximize the potential of Debio 1143 to become an innovative radio-chemo enhancing treatment for LA-SCCHN patients," commented Angela Zubel, Chief Development Officer, Debiopharm.

"This FDA assessment is a strong encouragement to expand investigations into other cancer types where the radio-sensitization effect of Debio 1143 could also provide further benefits over the current standard of care," expressed Sergio Szyldergemajn, Medical Director of Oncology at  Debiopharm.

Breakthrough Therapy Designation is intended to expedite the clinical development and review of medicines showing substantial improvements in serious or life-threatening conditions so that patients can access innovative therapies as soon as possible.

About Head and Neck Cancer
Squamous cell carcinoma of the head and neck (SCCHN) is the 6th most common cancer type worldwide, with more than half of patients diagnosed with locally-advanced (LA) disease.1-2 High-risk LA-SCCHN patients, including HPV negative  oropharyngeal cancer (OPC) patients and heavy smokers, face a poor prognosis even with current standard of care (SOC) as more than half of them will relapse.3-6 The consequences of LA-SCCHN have a heavy impact on quality of life and social interactions, affecting how patients look, talk, eat and breathe.7-9 Additional therapies are needed to ensure better outcomes for patients facing this devastating condition.

About Debio 1143 
Debio 1143 is a potential first-in-class oral antagonist of IAPs (inhibitor of apoptosis proteins), that sensitizes tumor cells to radio-chemo therapy by promoting programmed cell death and fostering anti-tumor immunity.  The clinical benefit observed in LA-SCCHN patients suggests that the integration of Debio 1143 into widely used CRT regimens is a promising investigational approach over a broad range of cancer types. Currently poised to enter into a Phase III, pivotal trial later this year in combination with CRT in Head & Neck cancer, the compound is also being investigated along with immune checkpoint inhibitors (PD-1/PD-L1) in various solid tumors. Over 200 patients have been treated so far with Debio 1143 in various indications and lines of treatment, showing an adequate and consistent safety profile across studies.

Debiopharm's commitment to cancer patients 
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally. 
For more information, please visit www.debiopharm.com  
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews  

Debiopharm Contact 
Dawn Haughton 
Communication Manager 
Tel: +41 (0)21 321 01 11 
235015@email4pr.com

References

ESMO. Head & Neck Cancers: Essentials for Clinicians. 2017. p. 1–6. http://oncologypro.esmo.org/content/download/113133/1971849/file/2017-ESMO-Essentials-for-Clinicians-Head-Neck-Cancers-Chapter-1.pdf (accessed August 2019) Perri F et al. Future Sci OA. 2018;5(1). Ang KK et al. N Engl J Med 2010;363:24-35. Marur S et al. Curr Opin Oncol. 2014;26(3):252–258 Magnes T et al. MEMO. 2017;10(4):220–223. Du E et al. Laryngoscope. 2019. Nelke K et al. Adv Clin Exp Med. 2014;23(6):1019–1027 Rettig EM et al. Cancer. 2016;122(12):1861–1870. Hernández-Vila C Plast Aesthet Res. 2015;3:203-210

SOURCE Debiopharm

More News From Technology - In The Headline

3-2-1-Cookoff! Astronauts to bake cookies with new test oven

Apr 7, 2020

CAPE CANAVERAL, Fla. — Forget reheated, freeze-dried space grub. Astronauts are about to get a new test oven for baking chocolate chip cookies from scratch. The next delivery to the International Space Station — scheduled for liftoff this weekend — includes the Zero G Oven. Chocolate chip cookie dough is already up there, waiting to pop into this small electric oven designed for zero gravity. Sample cookies baked just this week are also launching from Virginia on Northrop Grumman's Cygnus capsule, for the six station astronauts. The experiment explores the possibility of making freshly baked items for space travelers. With...

NASA moves up 1st all-female spacewalk to fix power unit

Apr 7, 2020

CAPE CANAVERAL, Fla. — NASA has moved up the first all-female spacewalk to this week because of a power system failure at the International Space Station. Astronauts Christina Koch (cook) and Jessica Meir (mere) will now venture out Thursday or Friday, instead of next Monday. A battery power controller failed over the weekend, prompting the change. The women will replace the broken component, rather than install new batteries, which was their original job. Last week, astronauts conducted two spacewalks to replace old space station batteries. They have three more spacewalks to go to finish the battery work. A battery-swapping spacewalk...

Museum of the Bible quietly replaces questioned artifact

Apr 7, 2020

OKLAHOMA CITY — The Museum of the Bible in Washington quietly replaced an artifact purported to be one of a handful of miniature Bibles that a NASA astronaut carried to the moon in 1971 after an expert questioned its authenticity. The move follows an announcement last year that at least five of 16 Dead Sea Scroll fragments that had been on display at the museum were found to be apparent fakes. The museum replaced the original microfilm Bible with one that was donated by an Oklahoma woman who wrote a book about the Apollo Prayer League, which arranged for Apollo...

No Deal: Auto workers strike against GM in contract dispute

Apr 7, 2020

DETROIT — More than 49,000 members of the United Auto Workers walked off General Motors factory floors or set up picket lines early Monday as contract talks with the company deteriorated into a strike. Workers shut down 33 manufacturing plants in nine states across the U.S., as well as 22 parts distribution warehouses. It wasn't clear how long the walkout would last, with the union saying GM has budged little in months of talks while GM said it made substantial offers including higher wages and factory investments. It's the first national strike by the union since a two-day walkout in...

Union votes to strike at General Motors' US plants

Apr 7, 2020

DETROIT — The United Auto Workers union announced Sunday that its roughly 49,000 workers at General Motors plants in the U.S. would go on strike just before midnight because contentious talks on a new contract had broken down. About 200 plant-level union leaders voted unanimously in favor of a walkout during a meeting Sunday morning in Detroit. Union leaders said the sides were still far apart on several major issues and they apparently weren't swayed by a GM offer to make new products at or near two of the four plants it had been planning to close, according to someone...

Sign up now!

About Us

In The Headline sought to bring professionalism back into journalism, bringing you only the most exclusive and the most impactive news from all over the globe.

Contact us: sales[at]intheheadline.com